Nexien Biopharma Financials
| NXEN Stock | USD 0.01 0.01 35.00% |
Nexien |
Understanding current and past Nexien Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Nexien Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Nexien Biopharma's assets may result in an increase in income on the income statement.
Nexien Biopharma Stock Summary
Nexien Biopharma competes with Cannara Biotech, Sonoma Pharmaceuticals, Aquestive Therapeutics, and Evoke Pharma. Nexien BioPharma, Inc. operates as a pharmaceutical company. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US65343D1000 |
| Business Address | 4340 East Kentucky |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | www.nexienbiopharma.com |
| Phone | 303 495 7583 |
| Currency | USD - US Dollar |
Nexien Biopharma Key Financial Ratios
Nexien Biopharma's financial ratios allow both analysts and investors to convert raw data from Nexien Biopharma's financial statements into concise, actionable information that can be used to evaluate the performance of Nexien Biopharma over time and compare it to other companies across industries.| Return On Equity | -40.7 | |||
| Return On Asset | -5.99 | |||
| Beta | 1.48 | |||
| Z Score | -8.4 |
Nexien Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nexien Biopharma's current stock value. Our valuation model uses many indicators to compare Nexien Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nexien Biopharma competition to find correlations between indicators driving Nexien Biopharma's intrinsic value. More Info.Nexien Biopharma is regarded fifth in return on equity category among its peers. It is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nexien Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nexien Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Nexien Biopharma Systematic Risk
Nexien Biopharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Nexien Biopharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was four with a total number of output elements of fifty-seven. The Beta measures systematic risk based on how returns on Nexien Biopharma correlated with the market. If Beta is less than 0 Nexien Biopharma generally moves in the opposite direction as compared to the market. If Nexien Biopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Nexien Biopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Nexien Biopharma is generally in the same direction as the market. If Beta > 1 Nexien Biopharma moves generally in the same direction as, but more than the movement of the benchmark.
Nexien Biopharma November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Nexien Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Nexien Biopharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Nexien Biopharma based on widely used predictive technical indicators. In general, we focus on analyzing Nexien Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Nexien Biopharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 35.58 | |||
| Information Ratio | 0.1299 | |||
| Maximum Drawdown | 216.63 | |||
| Value At Risk | (47.71) | |||
| Potential Upside | 59.09 |
Other Information on Investing in Nexien Pink Sheet
Nexien Biopharma financial ratios help investors to determine whether Nexien Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nexien with respect to the benefits of owning Nexien Biopharma security.